Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GLS | O94925 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366230 | 1.00 | L3MBTL1 (0.52) | L3MBTL1TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL9326518 | 0.90 | KDM4E (0.58) | L3MBTL1TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL31359581 | 0.88 | GLS (0.55) | L3MBTL1TSHRMAPK1GLSMTNR1B | |
| SCHEMBL18890099 | 0.87 | L3MBTL1 (0.54) | L3MBTL1TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL28293760 | 0.85 | L3MBTL1 (0.50) | L3MBTL1TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL11478284 | 0.84 | AKR1C3 (0.63) | L3MBTL1TSHRTDP1 | |
| SCHEMBL6366464 | 0.83 | GLS (0.54) | L3MBTL1GLSMTNR1BMTNR1AAOC3 | |
| SCHEMBL6366469 | 0.83 | GLS (0.54) | L3MBTL1GLSMTNR1BMTNR1AAOC3 | |
| SCHEMBL6366470 | 0.83 | GLS (0.54) | L3MBTL1GLSMTNR1BMTNR1AAOC3 | |
| SCHEMBL1433326 | 0.83 | L3MBTL1 (0.56) | L3MBTL1TSHRMAPK1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| EP-3383873-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2022-03-09 | — | — | EP | disclosed |
| CN-108349966-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-08-12 | — | — | US | disclosed |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-08-12 | — | — | US | disclosed |
| US-10981904-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-10981904-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-10323028-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-06-18 | — | — | US | disclosed |
| WO-2017093299-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-6838478-B2 | Amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| EP-0910573-B1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-14 | — | — | US | disclosed |
| US-6255301-B1 | CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-07-03 | — | — | US | disclosed |
| EP-0910573-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997046577-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | F2, SERPINC1, FGB | L3MBTL1 1224/4885TSHR 565/4885MAPK1 1069/4885 |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | L3MBTL1 1852/4885TSHR 1512/4885MAPK1 1407/4885 |
| US-10981904-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | L3MBTL1 1852/4885TSHR 1512/4885MAPK1 1407/4885 |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | GLS2, GLS, GLUL | L3MBTL1 1852/4885TSHR 1512/4885MAPK1 1407/4885 |
| US-10323028-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | L3MBTL1 1852/4885TSHR 1512/4885MAPK1 1407/4885 |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | L3MBTL1 1852/4885TSHR 1512/4885MAPK1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.